• We wish to exploit the need for effective treatment for nosocomial diarrhoea especially that caused byClostridium difficile disease (CDD). Patients treated with broad spectrum antibiotics are at greatest risk of CDD diarrhoea and many of those affected are hospitalised elderly patients with serious underlying illnesses. • Antibiotics can cause disruption of the normal intestinal flora, an important part of the immune system, leading to an overgrowth of CDD. Currently, some 2350 patients suffering from chronic CDD in a number of countries have been treated by faecal bacteriotherapy (FB), using samples collected from donors. • Although this procedure is reported, in a number of small studies, to be around 90% effective, it is hazardous, in that infection from the donor could be transmitted to the patient and it involves delivery of faecal samples into the duodenum via a nasal probe. • We propose to treat CDD using a modified FB to restore the patient’s original intestinal flora (employing samples collected from the patients themselves prior to their treatment) • We will produce novel enteric-coated capsules, containing processed freeze dried colonic flora that can be swallowed by a patient to restore their intestinal flora and immunise them against further infection by CDD. RFID tags will be employed to associate capsules with the relevant patient and assist with sample inventory. • 3 SMEs in 3 EU states and 5 distinguished research providers along with 1 OTHER SME in the coordination role will collaborate to provide the necessary technology to the project. The coordinator has previously coordinated an EU proposal and acted as a participant in projects over several Frameworks. • The outcome will be a non-antibiotic medicament to treat and prevent CDD The consortium plan to patent the IPR from the project, exploit and disseminate the technology.